Whether the amount of HIV DNA is associated with the subtype of HIV-1 after antiretroviral therapy (ART) has not been reported. In the present study, the amount of HIV DNA and RNA and CD4þT counts in blood and semen prior to and after 18 months of ART were compared in 48 patients infected by CRF01_AE, subtype B or CRF07_BC of HIV-1. Viral RNA was suppressed and CD4 cell count recovery achieved in all patients. The level of HIV DNA were similar before ART; however, patients with CRF01_AE had less HIV DNA after ART than those with subtype B and CRF07_BC infection. According to prediction of co-receptor usage by Geno2Pheno and PSSM in combination, more than 35.6% of clones for CRF01_AE were predicted as CXCR4-using before ART, whereas less than 6% of those for subtype B and CRF07_BC were predicted as CXCR4-using. After 18 months of ART, no CXCR4-using clones were predicted in any of the subtypes. Despite more HIV RNA and fewer CD4 þ T cells in patients with CRF01_AE before therapy, no significant differences (P > 0.05) in viral RNA or CD4 cell counts were observed between the subtypes after 18 months of ART. Thus, 18 months of antiretroviral therapy was more efficient in patients with CRF01_AE. Considering that successful ART dramatically reduces the viral load in both blood and semen, risks of sexual transmission of HIV were reduced, contributing to prevention of rapid spread of HIV among men who have sex with men in the region.
The Guangxi Zhuang Autonomous Region, located on the southern coast of China, has high prevalence of HIV type 1 in China (1) Consistent with changes in pattern in China (2) , sexual transmission has now become the dominant route of new HIV infections in Guangxi; in particular, the number of HIV-1-infected MSM has been increasing rapidly (3) . The risk of sexual transmission of HIV is correlated with the amount of virus in blood and semen (4, 5) . Combination ART is considered worldwide to reduce the amount of HIV in both blood and semen. Previous studies have shown that different subtypes of HIV respond differently (6, 7) or similarly (8) to ART, depending on the specific subtype.
In recent years, CRF01_AE has become a dominant strain among native HIV-infected individuals in China (9, 10) . CRF01_AE is associated with rapid disease progression (11, 12) and frequent chemokine receptor CXCR4-using (12, 13) . CXCR4-using virus is reportedly more sensitive to ART: a higher ratio of chemokine receptor CCR5-using virus after 24 weeks of ART has been reported (14) . In a recent study, CXCR4-using virus declined sharply in most patients after successful ART (15) . However, no study has reported changes in amounts of HIV DNA and associated co-receptors usage of different subtypes in patients receiving relatively long-term ART.
In this study, we compared the outcomes, including HIV DNA and co-receptor usage, of 18 months of ART among HIV-infected MSM in Guangxi. Despite the similar amounts of HIV DNA in the three subtypes before ART, after 18 months of ART HIV DNA exhibited a more significant decrease for subtype CRF01_AE than did the other subtypes. We also observed differences in changes in CXCR4-usage between the various subtypes of HIV.
MATERIALS AND METHODS

Study participants
Patients were recruited from the Antiviral Treatment Clinic, Guangxi Center for Disease Control and Prevention and AIDS Research Center, Ruikang Hospital affiliated to Guangxi University of Chinese Medicine from January 2015 to June 2017. Criteria for enrolling in the study were naive for ART, aged 18 years or older, without current sexually transmitted diseases (self-report and syphilis screening) and consent to participate in the study. All participants received ART, the regimen being tenofovir þ lamivudine þ efavirenz. Patients were followed up from the date of ART initiation at maximum intervals of 3 months. Paired samples of semen and blood were collected before and after 18 months of ART. Counseling regarding adherence, safe sex and condom use was given and recorded at every follow-up visit. Initially, 51 patients were enrolled; however, three who switched to another ART regimen were subsequently excluded. Thus, 48 patients were included in the final analysis. The participants included 22, 10, and 16 patients with CRF01_AE, subtype B and CRF07_BC, respectively. Relevant patient characteristics are presented in Table 1 . The study was approved by the Guangxi Center for Disease Control and Prevention Research Ethics Committee and all participants provided written informed consent.
Semen and blood samples
Semen samples were obtained by self-masturbation and collected in a dry sterile container, as previously described (16) . Briefly, 10 mL of blood were collected by vein puncture at the same visit into test tubes coated with EDTA. Samples were processed within 4 hr of collection. After liquefaction, semen samples were centrifuged (850 g, 10 min) to separate seminal plasma and seminal cells. Blood plasma was prepared from EDTA-treated blood at 1200 g at room temperature. PBMCs were isolated by Ficoll-Hypaque density gradient centrifugation. All samples were kept at À80°C in the lab of the HIV/AIDS Institute of Guangxi Center for Disease Control and Prevention.
CD4 þ T lymphocyte counts
Whole peripheral blood samples from each patient were tested on a BD FACS count analyzer (BD Biosciences San Diego, CA, USA). CD4þT counts were determined by three-color flow cytometry using human CD3þ, CD4þ and CD8þ cell markers. CD4þ T numbers per mL of whole blood were determined.
Quantification of HIV RNA in semen and blood
RNA was isolated from 200 mL of plasma using a QIAmp Viral RNA mini kit (Qiagen, Hilden, Germany). Plasma HIV RNA was quantified with real-time nucleic acid sequence based amplification (NucliSense Easy Q; bioM erieux, Lyon, France) according to the manufacturer's instructions, as previously described (17) . Uisng this assay, the sensitivity for viral RNA is 50 copies/mL. Amplification of HIV-1 pol gene and part of reverse transcriptase were performed as previously described to assess plasma RNA before ART (13) . PCR products were directly sequenced in both directions with sequencing primers using an ABI 3730 sequencer (Applied Biosystems, Foster, CA, USA).
Quantification of HIV DNA in seminal cells and blood PBMCs
Total DNA was extracted from the target cells using a QIAamp DNA blood mini kit (Qiagen). RT-PCR was performed in a 25 mL solution containing 2.5 mL of DNA target; 12.5 mL of Gene Expression Master Mix (Applied Biosystems), 1 mM primer and 0.2 mM probe under the following conditions: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min in an ABI 7500 PCR machine (Applied Biosystems). The sequences for the primers were: 5 0 -TGTGTGCCCGTCTGTTGTGT-3 0 (sense, HXB2 nt 557-576) and MH532: 5 0 -GAGTCCTGCG TCGAGAGAGC-3 0 (antisense, HXB2 nt 680-699). The probe was 5 0 -FAM-CAGTGGCGCCCGAACAGGGA-TAMRA-3 0 (HXB2 nt 633-652). The limit of detection was 10 copies/10 6 cells (18, 19) . 0 (antisense, HXB2 nt 7046-7026). The PCR products, including the V2-V5 region of the HIV-1 env were obtained. The gel-purified PCR products were further cloned into a TA vector (PMD18T simple vector, Takara, Shiga, Japan) and sequenced in both directions with sequencing primers using an ABI 3730 sequencer. Multiple HIV-1 negative controls were included with each PCR run to detect any possible contamination. At least six and 12 sequences for each RNA and DNA sample, respectively, were obtained.
Co-receptor usage and genotyping prediction
The sequences of the C2-V5 region were aligned with a reference sequence data set of all major subtypes and circulating recombinant forms using the Clustal W multiple sequence alignment program from MEGA 7. The sequences of the V3 region were translated into amino acid sequences using Bio Edit Sequence Alignment Editor 7.0 software. Chemokine receptor usage predictions based on V3 amino acid sequences were performed using Geno2pheno (20, 21) and WebPSMM (22). As both Geno2Pheno (false positive rate, FPR ¼ 10%) and PSSM are thought to overestimate the presence of CXCR4 viruses for CRF01_AE (23, 24), we followed the recently published algorithm that uses both Geno2pheno (FPR ¼ 5%) and PSSM in combination (13) with the aim of improving the analytic specificity and obtain more precise data. Tropism measured was considered to be concordant only if both algorithms detected pure CCR5 or CXCR4 co-receptor usage (13, 25) . Subtypes of the sequences for env and available gag/pol were determined by online tool HIV Blast of the Los Alamos HIV Database (26) .
Statistical analysis
Statistical analyses were conducted using the software of SPSS version 21.0 (SPSS, Chicago, IL, USA). Longitudinal changes were compared with Wilcoxon paired test. Viral load and CD4þT counts were compared between groups with the Mann-Whitney U test. Tropism genotypic among three subtypes was compared with x 2 test. All reported P-values are two-sided and considered to denote significance when < 0.05.
RESULTS
Successful ART suppresses HIV RNA and CD4þT counts recover
Before ART, patients with CRF01_AE infections had significantly greater amounts of HIV RNA in blood plasma than did those with subtype B and CRF07_BC infections (P < 0.05 and P < 0.01, respectively); however, viral RNA had become undetectable in all participants after 18 months of ART (Fig. 1a) . Amounts of HIV RNA in seminal plasma of patients with CRF01_AE infections were also greater than in participants with subtype B and CRF07_BC before ART; however, these differences were not statistically significant (both P > 0.05; Fig. 1b) . After 18 months of ART, HIV RNA had become undetectable in semen for all the subtypes in all participants (Fig. 1b) . Before ART, patients with CRF01_AE infection had lower CD4þT cell counts than did patients with subtype B and CRF07_BC infections (both P < 0.05; Fig. 1c) . However, there were no statistical differences between CD4þT cell counts of patients infected with the three subtypes after 18 months of ART; these counts had increased significantly for all three subtypes (all P < 0.01, Fig. 1c ).
Successful ART causes decreases in HIV DNA
Total HIV DNA was quantified for PBMCs and seminal cells and values compared between the three subtypes. Before ART, the median HIV DNA in PBMCs ranged from 5.23 log 10 to 5.43 log 10 copies per 10 6 cells for the three subtypes; no differences between subtypes were statistically significant (Fig. 2a) . After 18 months of ART, HIV DNA had decreased significantly for all three subtypes (P < 0.001), median amounts of HIV DNA in participants with CRF01_AE infections decreasing to 2.52 (IQR, 2.39-2.90) log 10 copies per 10 6 cells, which is significantly less than for subtype B and CRF07_BC (P < 0.05 and P < 0.001, respectively; Fig. 2a) . Similarly, there were no statistically significant differences between amounts of HIV DNA in seminal cells for the three subtypes before ART (Fig. 2b) . The median amount of HIV DNA in participants with CRF01_AE infections decreased from 4.58 log 10 to 2.37 log 10 copies per 10 6 seminal cells, which is significantly lower than the 3.11 and 3.22 log 10 copies per 10 6 cells for those with subtype B and CRF07_BC infections (P < 0.05 and P < 0.001, respectively; Fig. 2b) . The difference between subtype B and CRF07_BC was not statistically significant for the same time point.
Predicted co-receptor usage shifted after ART
More critical combinations of algorithms were next used to improve the specificity of algorithms for prediction of CXCR4-tropicin CRF01_AE strains. Predicted CXCR4-usasge of the clones was considered to be concordant only if confirmed by both algorithms, as previously described (13) . Before the ART, the ratio of CXCR4-usage for clones from CRF01_AE was higher than for the other subtypes of viruses (Table 2) . Before ART, about 41.9% (151/360) clones of PBMCs from patients with CRF01_AE were predicted as CXCR4-using, whereas there were only around 3.1% (8/260) and 2.0% (6/300) in PBMCs from patients with subtype B and CRF07_BC infections, respectively (P < 0.001). Before ART, this was true both for clones from viral DNA from semen and viral RNA from plasma. Additionally, the ratio of CXCR4_usage clones for CRF01_AE reached 40% in seminal cells and was about 35.2% in plasma, whereas all of these for subtype B and CRF07_BC were less than 6% (P < 0.001). After 18 months of ART and the associated successful suppression of viral RNA, prediction could only be performed by clones for DNA from PBMCs and seminal cells. No CXCR4-using clones were predicted in any of the subtypes, that is, all clones were predicted as CCR5-using ones (Table 2 ).
DISCUSSION
We found that the outcomes of ART differed among participants with CRF01_AE, subtype B and CRF07_BC infections (Figs. 1, 2 ). Prior to ART, the amount of HIV DNA was similar among the three subtypes, but after ART, the HIV DNA in CRF01_AE showed the most significant decrease. In addition, a higher proportion of CXCR4-using was predicted for CRF01_AE than for subtype B and CRF07_BC. After 18 months of ART, none of the clones in any of the subtypes were predicted as CXCR4-using (Table 2 ). This finding is consistent with a previous study in which antiretroviral therapy preferentially suppressed the X4 virus (15) . The dramatic decline in HIV DNA in CRF01_AE may be associated with its frequent CXCR4-using. Participants with CRF01_AE infection had greater amounts of HIV RNA and lower CD4þT counts prior to ART; however, HIV RNA in in both blood and semen had become undetectable after 18 months of ART. CD4þT counts increased to the same as those in participants with subtypes B and CRF07_BC (Fig. 1) . Despite all three groups having the same amount of HIV DNA before ART, amounts of HIV DNA were least for CRF01_AE after ART (Fig. 2) . Considering the goal of HIV eradiation, some studies suggest that total HIV DNA can be used to estimate the reservoir in patients on ART (27, 28) ; smaller reservoirs predicting better outcomes (29) (30) (31) . Thus, our findings indicate that although patients with CRF01_AE showed more severe disease prior to ART, this therapy was more effective after 18 months of antiretroviral therapy in these patients than in those infected with the other subtypes.
Although other researchers have reported divergent patterns and intermittent seminal viral shedding despite an undetectable viral load in blood in 1.8-48% of patients receiving ART (32) (33) (34) (35) (36) (37) , in the current study, seminal HIV RNA had become undetectable after 18 months of ART in all patients (Fig. 1) . Seminal viral shedding of HIV may be associated with co-infection such as cytomegalovirus (34) , genital inflammations (38), differences in blood viral loads (37) , ART regimen (39) or duration of ART (36) . In the current study, the undetectable seminal viral load we found after ART may be attributable to the relatively longer duration of ART, which differs from our previous study with only 6 months of ART (16) . Our result is consistent with those of previous studies for 6 months (40) or more than 3 years of ART (36, 41) . Further studies are still needed to confirm our results in more patients receiving prolonged ART and over more intervals. The risk of sexual transmission of HIV is reportedly correlated with the amount of genital HIV RNA (4, 42) . Our study confirmed that effective ART can reduce HIV in both blood and semen of MSM with all subtypes in HIV infection, thus preventing rapid spread of HIV among MSM in the region.
In the current study, we predicted viral tropisms by a combination of two genotypic methods. Although overestimation can occur with use of a single algorithm (24), a combination of Geno2Pheno (false positive rate ¼ 5%) and PSMM reportedly improves specificity (13, 25) . In the future, confirmation by phenotypic assays (43) needs to be developed; this would further incorporate intermediate transitional dual/mixed-tropic (CXCR4 and/or CCR5) virus (44) .
In summary, in this study we found that ART has a greater impact on the amount of HIV DNA in participants with CRF01_AE infection than in those À, no positive clones; X4, CXCR4 or dual /mixed (CXCR4/CCR5)-using; R5, CCR5-using only.
with subtype B and CRF07_BC infection. In addition, 18 months of ART reduced the HIV viral load in blood and semen for all subtypes, thus preventing rapid spread of HIV among MSM in the region.
